Avoid common mistakes on your manuscript.
Correction to: International Journal of Clinical Oncology https://doi.org/10.1007/s10147-021-01920-0
In the original publication, the name of the fourth author should be: Takafumi Sangai and his affiliation should be:
Department of Breast and Thyroid Surgery, Chiba University Hospital, Chiba, Japan
The corrected name and affiliation are given in this correction.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Aogi, K., Watanabe, K., Kitada, M. et al. Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). Int J Clin Oncol 26, 1237 (2021). https://doi.org/10.1007/s10147-021-01940-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-021-01940-w